Ahead of Christmas, GlaxoSmithKline has been identified as an investment option that may benefit over the Christmas period.
Nick Raynor, investment adviser at The Share Centre, observed that GlaxoSmithKline has an impressive product range as well as an impressive yield .
Several of the company's products should prove popular over the Christmas period, according to Mr Raynor.
"Lucozade to recharge the batteries after spending too much time playing with the children's toys; Horlicks to help send you off to sleep when counting sheep just won't do; Panadol to help get over the predicted hangovers; and Niquitin for that New Year's resolution to quit smoking once again," he said.
"These are just some of the company's products and what adds to GlaxoSmithKlines's attraction is that there are so many more products in the pipeline waiting to come to market."
Founded in 2000, GlaxoSmithKline is a global pharmaceutical, biologics, vaccines and consumer healthcare company.
It is, in fact, the world's third largest pharmaceutical company measured by revenues.
GlaxoSmithKline identified as worthwhile investment
GlaxoSmithKline identified as worthwhile investment
Tue, 07 Dec 2010
Recommended links
Investment enquiry formTerm accounts explained
National savings explained
Preference shares
What are higher risk investments
Investment trusts
The Stock Market
Property development
Ethical investments
Best savings accounts
Complaints against personal investment firms have risen, reveals FSA
Investors told double-dip recession is unlikely
Britons told to consider making pensions investment
Guaranteed investment income from Aegon
Property investment portfolio wins award
| Stocks & Shares news |
|---|
| Investors happy to make own decisions but lack SIPP knowledge, survey finds - Tue, 05 Apr 2011 |
| Investors put off switching Isas by low rates and fear of mistakes - Thu, 31 Mar 2011 |
| Investors shunning banks when taking out an Isa - Tue, 22 Mar 2011 |
| More News |
